

Synthesis of Imidazo[4,5-*e*]-*as*-triazine(6-Azapurine)Derivatives

Synthesis of some derivatives in the novel ring system, imidazo[4,5-*e-as*]-triazine(6-azapurine) (Va-f), has been described. 2-Benzyl-6-bromo-*as*-triazine-3,5(2*H*, 4*H*)-dione (1-benzyl-5-bromo-6-azauracil)(I) reacted smoothly with ammonia and benzylamine, to give 6-amino-(IIa) and 6-benzylamino-2-benzyl-*as*-triazine-3,5(2*H*, 4*H*)-dione(IIb) respectively. Selective thionation of these amino derivatives(IIa,b), by heating with phosphorus pentasulphide in pyridine, to lead to 6-amino-(IIIa) and 6-benzylamino-2-benzyl-*as*-triazin-3(2*H*)-one-5(4*H*)-thione(IIIb), effectively proceeded, and subsequent aminodethiolation of the latter (IIIa,b) also readily went on to afford 5,6-diamino-(IVa), 5-amino-6-benzylamino-(IVb), 5-benzylamino-6-amino-(IVc), and 5,6-dibenzylamino-2-benzyl-*as*-triazin-3(2*H*)-one (IVd).

An oxidative mode of cyclisation, by heating with ethyl orthoformate or benzaldehyde in nitrobenzene under reflux for a few hours, furnished a successful procedure for the preparation of 2-benzyl-5*H*-(Va) and 2,5-dibenzyl-imidazo[4,5-*e*]-*as*-triazin-3(2*H*)-one(Vb), or 2-benzyl-5*H*-(Vc), 2,5-dibenzyl-(Vd), and 2,7-dibenzyl-6-phenyl-imidazo[4,5-*e*]-*as*-triazin-3(2*H*)-one (Ve), respectively. An attempted benzylation of Vc yielded a mixture of the products which consisted of Vd, as a minor component, and the alternative isomer assigned tentatively to 2,4-dibenzyl-6-phenyl-imidazo[4,5-*e*]-*as*-triazin-3(2*H*)-one(Vf), as a major one, however, it was not contaminated with any isolable amount of Ve.

Studies on 2-aza- and 8-azapurine derivatives,¹⁾ for potential antimetabolites or the chemistry *per se*, have recently attracted the attention of very numerous laboratories, but to our best knowledge, any report concerned with 6-aza analogue of purine has not yet been found. Notable biological activities of some compounds in the aza analogues of purine²⁾ and pteridine,³⁾ further, isolation of a naturally occurring pigment, a compound belonging to the pyrazolo[4,3-*e*]-*as*-triazine,⁴⁾ prompted us to report the synthesis of some derivatives in the novel ring system of imidazo[4,5-*e*]-*as*-triazine(6-azapurine) (Va-f).⁵⁾

2-Benzyl-5,6-diamino-*as*-triazin-3(2*H*)-one (IVa: R=C₆H₅CH₂, R'=R''=H) was heated with an excess of ethyl orthoformate in nitrobenzene under reflux for 5 hours, to afford 2-benzyl-imidazo[4,5-*e*]-*as*-triazin-3(2*H*)-one (Va) (R=C₆H₅CH₂, R'=R''=H: mp 263—264°, colourless needles, IR ν_{\max}^{KBr} cm⁻¹: 1640 (>N-CO), 3200 (NH), NMR (in CF₃CO₂D) τ : 0.72 (1H, s, C⁶-H), 2.52 (5H, s, C₆H₅), 4.32 (2H, s, >N-CH₂-C₆H₅), 72% yield, *Anal.* Calcd. for C₁₁H₉ON₃: C, 58.14; H, 3.99; N, 30.82. Found: C, 58.18; H, 4.00; N, 30.54). The amine IVa also reacted smoothly with benzaldehyde, in a similar reaction condition, to give 2-benzyl-6-phenyl-imidazo[4,5-*e*]-*as*-triazin-3(2*H*)-one (Vc) (R=C₆H₅CH₂, R'=H, R''=C₆H₅: mp >300°, colourless needles, IR ν_{\max}^{KBr} cm⁻¹: 1640 (>N-CO), 3380 (NH), UV $\lambda_{\text{EIOH}}^{\max}$ nm (log ϵ): 256 (4.11),

- 1) J. Gut, *Advances in Heterocyclic Compounds*, **1**, 237 (1963); A. Albert, *J. Chem. Soc. (B)*, **1966**, 427; J.W. Bunting and D.D. Perrin, *ibid.*, 433 (1966); A. Albert and K. Tratt, *J. Chem. Soc. (C)*, **1968**, 344; A. Albert, *ibid.*, **1968**, 2076.
- 2) R.O. Roblin, Jr., J.O. Lampen, J.P. English, Q.P. Cole, and J.R. Vaughan, Jr., *J. Am. Chem. Soc.*, **67**, 290 (1945); J.A. Montgomery, *Cancer Res.*, **19**, 447 (1959); J. Baddiley, J.G. Buchanan, and G.O. Osborne, *J. Chem. Soc.*, **1958**, 1651, 3606; S. Yamada, T. Mizoguchi, and A. Ayata, *Yakugaku Zasshi*, **77**, 455 (1957); A. Dornow and J. Helberg, *Chem. Ber.*, **93**, 2001 (1960); E. Richter and E.C. Taylor, *J. Am. Chem. Soc.*, **78**, 5848 (1956).
- 3) W. Pfeiderer and K.-H. Shundehutte, *Ann.*, **615**, 42 (1958); G. Blankenhorn and W. Pfeiderer, *Chem. Ber.*, **105**, 3334 (1972); E.C. Taylor and F. Sowinski, *J. Am. Chem. Soc.*, **90**, 1374 (1968); *idem, ibid.*, **91**, 2143 (1969); G.D. Daves, R.K. Robins, and C.C. Cheng, *J. Am. Chem. Soc.*, **83**, 3904 (1961); C. Temple, Jr., C.L. Kussner, and J.A. Montgomery, *J. Org. Chem.*, **40**, 2205 (1975); F. Yoneda and T. Nagamatsu, *J. Am. Chem. Soc.*, **95**, 5735 (1973); F. Yoneda and T. Nagamatsu, *Chem. Pharm. Bull. (Tokyo)*, **23**, 2001 (1975); F. Yoneda and T. Nagamatsu, *Bull. Chem. Soc. Japan*, **48**, 2884 (1975); F. Yoneda, T. Nagamatsu, and K. Shinomura, *J. Chem. Soc. Perkin I*, **1976**, 713.
- 4) H. Lindner and G. Schaden, *Chem. Ber.*, **105**, 1949 (1972).
- 5) This work was partly presented at the 96th annual meeting of Pharmaceutical Society of Japan, Nagoya, April 1976.

316 (4.42), NMR (in $\text{CF}_3\text{CO}_2\text{D}$) τ : 1.46—2.25 (5H, m, C_6H_5), 2.51 (5H, s, C_6H_5), 4.36 (2H, s, $>\text{N}-\text{CH}_2-\text{C}_6\text{H}_5$), 77% yield, *Anal.* Calcd. for $\text{C}_{17}\text{H}_{13}\text{ON}_5$: C, 67.32; H, 4.32; N, 23.09. Found: C, 67.08; H, 4.22; N, 23.11). This type of ring closure, an oxidative mode of cyclisation, was applied to the benzylamines, IVb ($\text{R}=\text{R}'=\text{C}_6\text{H}_5\text{CH}_2$, $\text{R}''=\text{H}$) and IVc ($\text{R}=\text{R}''=\text{C}_6\text{H}_5\text{CH}_2$, $\text{R}'=\text{H}$), to embody the formation of 2,5-dibenzyl-imidazo[4,5-*e*]-*as*-triazin-3(2*H*)-one (Vb) ($\text{R}=\text{R}'=\text{C}_6\text{H}_5\text{CH}_2$, $\text{R}''=\text{H}$: mp 162° , colourless needles, IR $\nu_{\text{max}}^{\text{KBr}}$ cm^{-1} : 1660 ($>\text{N}-\text{CO}$), NMR (in CDCl_3) τ : 1.89 (1H, s, C^6-H), 2.25—2.75 (10H, m, $\text{C}_6\text{H}_5 \times 2$), 4.53 (2H, s, $>\text{N}-\text{CH}_2-\text{C}_6\text{H}_5$), 4.84 (2H, s, $>\text{N}-\text{CH}_2-\text{C}_6\text{H}_5$), 38% yield, *Anal.* Calcd. for $\text{C}_{18}\text{H}_{15}\text{ON}_5$: C, 68.13; H, 4.76; N, 22.07. Found: C, 67.95; H, 4.65; N, 21.94), 2,5-dibenzyl-6-phenyl-imidazo[4,5-*e*]-*as*-triazin-3(2*H*)-one (Vd) ($\text{R}=\text{R}'=\text{C}_6\text{H}_5\text{CH}_2$, $\text{R}''=\text{C}_6\text{H}_5$: mp $186-187^\circ$, colourless needles, IR $\nu_{\text{max}}^{\text{KBr}}$ cm^{-1} : 1670 ($>\text{N}-\text{CO}$), UV $\lambda_{\text{max}}^{\text{EtOH}}$ nm (log ϵ): 262 (4.26), 290 (4.18), 369 (3.98), NMR (in CDCl_3) τ : 2.08—3.00 (15H, m, $\text{C}_6\text{H}_5 \times 3$), 4.49 (2H, s, $>\text{N}-\text{CH}_2-\text{C}_6\text{H}_5$), 4.65 (2H, s, $>\text{N}-\text{CH}_2-\text{C}_6\text{H}_5$), 41% yield, *Anal.* Calcd. for $\text{C}_{24}\text{H}_{19}\text{ON}_5$: C, 73.27; H, 4.87; N, 17.80. Found: C, 73.07; H, 4.80; N, 17.73), and 2,7-dibenzyl-6-phenyl-imidazo[4,5-*e*]-*as*-triazin-3(2*H*)-one (Ve) ($\text{R}=\text{R}''=\text{C}_6\text{H}_5\text{CH}_2$, $\text{R}'=\text{C}_6\text{H}_5$: mp 223° , pale yellow needles, IR $\nu_{\text{max}}^{\text{KBr}}$ cm^{-1} : 1628 ($>\text{N}-\text{CO}$), UV $\lambda_{\text{max}}^{\text{KBr}}$ nm (log ϵ): 257 sh (3.66), 315 (4.27), NMR (in $\text{CF}_3\text{CO}_2\text{D}$) τ : 1.58—2.92 (15H, m, $\text{C}_6\text{H}_5 \times 3$), 4.20 (2H, s, $>\text{N}-\text{CH}_2-\text{C}_6\text{H}_5$), 4.36 (2H, s, $>\text{N}-\text{CH}_2-\text{C}_6\text{H}_5$), 51% yield, *Anal.* Calcd. for $\text{C}_{24}\text{H}_{19}\text{ON}_5$: C, 73.27; H, 4.87; N, 17.80. Found: C, 73.34; H, 4.92; N, 17.94), respectively.




Fig. 1

An appropriate synthetic approach to the amines (IVa—c), promising to build up the imidazo[4,5-*e*]-*as*-triazine ring, or the like, has been presumably sought but remained as yet unsettled for these several years. The synthetic scheme presented here consists of three steps: (i) Aminodebromination of 2-benzyl-6-bromo-*as*-triazine-3,5(2*H*, 4*H*)-dione (I); (ii) Selective thionation of 6-amino-(IIa) and 6-benzylamino-2-benzyl-*as*-triazine-3,5(2*H*, 4*H*)-dione (IIb) to 6-amino-(IIIa) and 6-benzylamino-2-benzyl-*as*-triazin-3(2*H*)-one-5(4*H*)-thione (IIIb), respectively; (iii) Aminodethiolation of the thiones (IIIa, b) to the 5,6-diamino-2-benzyl-*as*-triazin-3(2*H*)-ones (IVa—d). I (mp 187°)⁶⁾ was converted, by heating with aqueous




Fig. 2

ammonia, in the presence of catalytic amount of copper, under pressure, to IIa ($\text{R}=\text{C}_6\text{H}_5\text{CH}_2$, $\text{R}''=\text{H}$: mp $291-292^\circ$, colourless crystals, IR $\nu_{\text{max}}^{\text{KBr}}$ cm^{-1} : 1670 ($>\text{N}-\text{CO}$), 1705 ($>\text{N}-\text{CO}$), 3280, 3430 (NH_2), NMR (in $\text{DMSO}-d_6$) τ : 2.61 (5H, s, C_6H_5), 3.77 (2H, s, NH_2), 5.09 (2H, s, $>\text{N}-\text{CH}_2-\text{C}_6\text{H}_5$), 91% yield) and with benzylamine to IIb ($\text{R}=\text{R}''=\text{C}_6\text{H}_5-\text{CH}_2$: mp $224-225^\circ$, colourless needles, IR $\nu_{\text{max}}^{\text{KBr}}$ cm^{-1} : 1660 ($>\text{N}-\text{CO}$), 1705 ($>\text{N}-\text{CO}$), 3360 (NH), NMR (in $\text{DMSO}-$

6) K. Kaji, H. Nagashima, Y. Okuda, M. Kato, and M. Takagi, Abstracts of the 89th annual meeting of Pharmaceutical Society of Japan, p. 250 (Nagoya, April 1969).

Gifu College of Pharmacy
East 5-6-1, Mitahora, Gifu

KENJI KAJI
MASAMI KAWASE

Received July 5, 1976